Clinical Trials Logo

Head and Neck Carcinoma clinical trials

View clinical trials related to Head and Neck Carcinoma.

Filter by:

NCT ID: NCT05115825 Recruiting - Clinical trials for Head and Neck Carcinoma

Pain Management for Head and Neck Cancer Survivors

Start date: April 1, 2019
Phase: N/A
Study type: Interventional

This clinical trial improves an existing pain management program and tests its effect on head and neck cancer survivors. This trial aims to find a better program to improve pain-related physical functioning, mood, and quality of life in a sample of individuals who have undergone treatment for head and neck cancer.

NCT ID: NCT05077072 Recruiting - Clinical trials for Head and Neck Carcinoma

Interdisciplinary Interventions to Address Pain Management Among Head and Neck Cancer Patients

Start date: October 8, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial compares different pain management interventions (standard of care [SOC], neurofeedback [NFB] training, and compassionate high alert team [CHAT]) in patients diagnosed with head and neck cancer who are at risk of developing non-medical opioid use (NMOU). The current standard treatment includes regular clinic visits and supportive care and counseling (including topics like patient-doctor communication, cancer care goals, financial issues counseling, and other topics). NFB training is a type of therapy that uses an electroencephalograph (EEG) and a computer software program to measure brain wave activity. The goal of NFB is to help teach patients with pain how to change their own brain waves to lower their feelings of pain and help improve their quality of life. CHAT is a supportive care intervention that includes symptom and pain management, counseling (about pain, symptoms, opioid use and safety, stress, and quality of life), and support for patients and their family members. NFB and CHAT may help to manage pain and lower patient use of opioids.

NCT ID: NCT05075980 Recruiting - Clinical trials for Head and Neck Carcinoma

HEADLIGHT: Hypofractionated Proton Therapy for Head and Neck Cancers

Start date: February 16, 2022
Phase: Phase 2
Study type: Interventional

This clinical trial tests whether intensity modulated proton therapy after surgery works to shrink tumors in patients with head and neck cancer. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors.

NCT ID: NCT05018208 Recruiting - Clinical trials for Malignant Solid Neoplasm

Remote Monitoring in Cancer Care: A Platform Study

Start date: December 15, 2021
Phase:
Study type: Observational

This study investigates a device that closely monitors vital signs, as well as a smartphone application (app) that allows patients to respond to different questions and tests that will monitor for new symptoms. This study may help researchers understand if wearing the device is a better tool than standard vital sign assessment tools done only while at the doctor's office or hospital, and if using the smartphone app is a better tool than standard assessment tools used while in the doctor's office or hospital.

NCT ID: NCT04890834 Recruiting - Clinical trials for Head and Neck Carcinoma

Dyadic Yoga Intervention for the Improvement of Healthcare Utilization and Quality of Life in Patients With Head and Neck Cancer Undergoing Chemoradiation and Their Caregivers

Start date: January 28, 2021
Phase: N/A
Study type: Interventional

This study evaluates if partner-based (dyadic) yoga programs may improve the quality of life of patients with head and neck cancer undergoing chemoradiation and their caregivers, and if it is a cost-effective option. Yoga programs may decrease how often patients come to the hospital during and after treatment with chemoradiation, and improve the quality of life for both patients and caregivers.

NCT ID: NCT04870762 Recruiting - Clinical trials for Head and Neck Carcinoma

Customized 3D Printed Oral Stents During Head and Neck Radiotherapy

Start date: May 26, 2021
Phase: Phase 2
Study type: Interventional

This clinical trial studies the effect of customized 3 dimensional (3D) printed oral tents on patients with head and neck cancer who are receiving radiotherapy. Oral stents are made from the impression of patients' mouth and cover patients' teeth and gums during radiation therapy. A customized, 3D-printed oral stent may help to reduce mouth blisters and/or sores that may develop in patients while receiving head and neck radiation therapy.

NCT ID: NCT04475640 Recruiting - Breast Carcinoma Clinical Trials

Cancer Genetic Testing in Ethnic Populations

Start date: December 13, 2019
Phase: N/A
Study type: Interventional

This clinical trial examines the integration of cancer genetic testing in various ethnic populations. Studying individuals and families at risk of cancer may help identify cancer genes and other persons at risk. The information from this study may provide an opportunity for cancer risk stratification and individualized screening in these ethnic populations.

NCT ID: NCT04151082 Recruiting - Clinical trials for Head and Neck Carcinoma

High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors

Start date: October 31, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effect and best dose of steroid therapy (prednisone or methylprednisolone) in improving symptoms of late radiation-associated lower cranial neuropathy in oropharyngeal cancer survivors. Steroid therapy with prednisone or methylprednisolone may help to improve symptoms associated with late radiation-associated lower cranial neuropathy.

NCT ID: NCT04147494 Recruiting - Breast Carcinoma Clinical Trials

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Start date: November 5, 2019
Phase: Early Phase 1
Study type: Interventional

This phase I trial studies a new imaging technique called FAPi PET/CT to determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulate in normal and cancer tissues in patients with non-prostate cancer. The research team also want to know whether what they see on PET/CT images represents the tumor tissue being excised from the patient's body. The research team is also interested to investigate another new imaging technique called PSMA PET/CT. Participants will be invited to undergo another PET/CT scan, with the PSMA tracer (68Ga-PSMA-11). This is not required but just an option for volunteer patients. Patients who have not received an 18F-FDG PET/CT within one month of enrollment will also undergo an FDG PET/CT scan. The PET/CT scanner combines the PET and the CT scanners into a single device. This device combines the anatomic (body structure) information provided by the CT scan with the metabolic information obtained from the PET scan. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of, in the case of this research, 68Ga-PSMA-11 and 68Ga-FAPi, and 18F-FDG (if applicable). Because some cancers take up 68Ga-PSMA-11 and/or 68Ga-FAPi it can be seen with PET. CT utilizes x-rays that traverse the body from the outside. CT images provide an exact outline of organs where it occurs in patient's body. FAP stands for Fibroblast Activation Protein. FAP is produced by cells that surround tumors. The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the future provide additional information about various cancers. PSMA stands for Prostate Specific Membrane Antigen. This name is incorrect as PSMA is also found in many other cancers. The function of PSMA is not well understood but imaging studies have shown that PSMA can be detected with PET in many non-prostate cancers. Imaging FAP with PET/CT may in the future provide additional information about various cancers.

NCT ID: NCT03993353 Recruiting - Cancer Clinical Trials

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

Start date: April 7, 2020
Phase: Phase 2
Study type: Interventional

This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.